RT Journal Article
SR Electronic
T1 Deciphering how early life adiposity influences breast cancer risk using Mendelian randomization
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.22.21259310
DO 10.1101/2021.06.22.21259310
A1 Vabistsevits, Marina
A1 Smith, George Davey
A1 Sanderson, Eleanor
A1 Richardson, Tom G
A1 Lloyd-Lewis, Bethan
A1 Richmond, Rebecca C
YR 2021
UL http://medrxiv.org/content/early/2021/06/27/2021.06.22.21259310.abstract
AB Studies suggest that adiposity in childhood may reduce the risk of breast cancer in later life. The biological mechanism underlying this effect is unclear but is likely to be independent of body size in adulthood. Using a Mendelian randomization framework, we investigated 18 hypothesised mediators of the protective effect of childhood adiposity on later-life breast cancer, including hormonal, reproductive, physical, and glycaemic traits.Our results indicate that, while most of the hypothesised mediators are affected by childhood body size, only IGF-1, testosterone, age at menarche and age at menopause influenced breast cancer risk. However, accounting for those traits in multivariable Mendelian randomization showed that the protective effect of childhood body size still remained. This suggests either a direct effect of childhood body size on breast cancer risk or mediation via other pathways not considered.Our work presents a framework for the systematic exploration of potential biological mediators of disease in Mendelian randomization analysis.Competing Interest StatementTGR is employed part-time by Novo Nordisk outside of this work. All other authors declare no competing interests.Funding StatementBLL - University of Bristol (Vice-Chancellor's fellowship) and the Academy of Medical Sciences; RCR - de Pass Vice Chancellor's research fellowship at the University of Bristol; MV - University of Bristol Alumni Fund: Professor Sir Eric Thomas Scholarship; MV, GDS, ES, TGR, RR work in the Medical Research Council Integrative Epidemiology Unit at the University of Bristol supported by Medical Research Council (MC_UU_00011/1, MC_UU_00011/2 and MC_UU_00011/4); This work was also supported by a Cancer Research UK programme grant (the Integrative Cancer Epidemiology Programme) (C18281/A19169). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All analyses conducted in this study are based on data from summary-level datasets (whose ethical approval can be found in the corresponding studies referenced) or the UK Biobank study (Research Ethics Committee approval number: 11/NW/0382, app #15825).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe availability of all data analysed in this study has been referenced throughout the manuscript and supplementary materials.